News and Trends 25 Aug 2016
Galapagos Hangs On: Filgotinib enters Phase III for Rheumatoid Arthritis
After losing AbbVie as a partner, Galapagos has pressed on with Gilead in the development of filgotinib for rheumatoid arthritis. Phase III trials have officially begun! Galapagos is making progress…